The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids
ConclusionIn patients with treated PsA, IRs of MI, stroke and revascularization were low for all systemic treatments evaluated. Although the number of events was small, apremilast exposure did not signal potential acute cardiovascular harm and was not associated with a material increase in the risk of these serious cardiac events.
Source: Rheumatology - Category: Rheumatology Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Corticosteroid Therapy | Databases & Libraries | Heart | Heart Attack | Psoriatic Arthritis | Rheumatology | Stroke | Study | USA Health